Nurix Therapeutics, Inc. - Common stock (NRIX)

Nurix Therapeutics develops targeted cancer and immune disorder therapies, supported by partnerships with leading pharma companies.

This clinical-stage biotech develops antibody therapies for cancer and infectious diseases, leveraging proprietary discovery platforms.

This clinical-stage biotech develops targeted cancer therapies, leveraging bispecific antibodies and strategic industry partnerships.

Krystal Biotech develops redosable gene therapies targeting rare skin diseases, with a late-stage clinical pipeline and expanding portfolio.

Scholar Rock develops therapies for neuromuscular and oncological diseases, leveraging a proprietary platform to target unmet medical needs.

San Francisco, CA – October 22, 2025 – Nurix Therapeutics (NASDAQ: NRIX) has captured significant market attention, with its stock experiencing a notable surge following the announcement of the initiation of its pivotal Phase 2 DAYBreak clinical study. This critical advancement focuses on bexobrutideg (NX-5948), an investigational Bruton's tyrosine kinase (BTK) degrader,

US stock futures up, Apogee Enterprises, Levi Strauss, VolitionRX, USANA Health Sciences, Nurix Therapeutics report results.

Nurix Therapeutics Q3 2025 results miss revenue and EPS estimates, triggering a stock drop. The biotech firm also announced pivotal trial plans for its lead drug candidate.

Wondering what's happening in today's after-hours session? Stay tuned for the latest updates on stock movements.

The company also shared promising early data from its blood cancer drug bexobrutideg and said it plans to begin late-stage trials later this year.

Let's have a look at what is happening on the US markets after the closing bell on Wednesday. Below you can find the top gainers and losers in today's after hours session.